Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Aradhana Kari

Aradhana Kari

Regulatory Coordinator II

Cancer Center Division

Collaboration(6)

Setsuko Chambers
Brianna Denton
Carolyn Lane
Mitzi Miranda
Angelique Thornton

Page 1 of 2

Grants(4)

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
Active·2023·$0 / $560.9K·
External
ovarian cancer, combination therapy, platinum-resistant, peritoneal cancer, fallopian-tube cancer
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active·2023·$0 / $270.2K·
External
clinical trials, cancer treatment, immunotherapy, chemotherapy, women's health
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platnum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive
2023·$0 / $217.6K·
External
cancer therapy, clinical trial, pharmacology, immunotherapy, drug development
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZNc3 in Combination with Niraparib in Subjects with Platinum Resistant Ovarian Cancer
2023·$0 / $18.4K·
External
ovarian cancer, combination therapy, dose escalation, dose expansion, platinum-resistant